PACIRA PHARMACEUTICALS INC's ticker is PCRX and the CUSIP is 695127100. A total of 256 filers reported holding PACIRA PHARMACEUTICALS INC in Q3 2020. The put-call ratio across all filers is 2.34 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,434,777 | -27.1% | 46,767 | -4.8% | 0.00% | 0.0% |
| Q2 2023 | $1,969,078 | -0.5% | 49,143 | +1.4% | 0.00% | -25.0% |
| Q1 2023 | $1,978,286 | +36.5% | 48,475 | +29.1% | 0.00% | +33.3% |
| Q4 2022 | $1,449,737 | -69.8% | 37,550 | -58.3% | 0.00% | -72.7% |
| Q3 2022 | $4,795,000 | -11.1% | 90,154 | -1.8% | 0.01% | -8.3% |
| Q2 2022 | $5,391,000 | +31.2% | 91,806 | +70.5% | 0.01% | +50.0% |
| Q1 2022 | $4,109,000 | +40.1% | 53,848 | +11.5% | 0.01% | +33.3% |
| Q4 2021 | $2,932,000 | +10.6% | 48,309 | +3.4% | 0.01% | 0.0% |
| Q3 2021 | $2,650,000 | -1.0% | 46,731 | +6.6% | 0.01% | 0.0% |
| Q2 2021 | $2,677,000 | +4.0% | 43,836 | +16.5% | 0.01% | 0.0% |
| Q1 2021 | $2,573,000 | +19.1% | 37,640 | +5.6% | 0.01% | 0.0% |
| Q4 2020 | $2,161,000 | -42.5% | 35,631 | -42.7% | 0.01% | -45.5% |
| Q3 2020 | $3,757,000 | +2.2% | 62,170 | -10.5% | 0.01% | 0.0% |
| Q2 2020 | $3,675,000 | +81.1% | 69,493 | +15.9% | 0.01% | +57.1% |
| Q1 2020 | $2,029,000 | -7.6% | 59,948 | +27.1% | 0.01% | 0.0% |
| Q4 2019 | $2,196,000 | +136.9% | 47,170 | +93.8% | 0.01% | +250.0% |
| Q3 2019 | $927,000 | -5.3% | 24,344 | +8.2% | 0.00% | -33.3% |
| Q2 2019 | $979,000 | +107.9% | 22,497 | +81.3% | 0.00% | +50.0% |
| Q1 2019 | $471,000 | -64.2% | 12,409 | -56.6% | 0.00% | -60.0% |
| Q4 2018 | $1,315,000 | +92.0% | 28,578 | +105.4% | 0.01% | +150.0% |
| Q3 2018 | $685,000 | +613.5% | 13,916 | +365.0% | 0.00% | – |
| Q2 2018 | $96,000 | +68.4% | 2,993 | +64.4% | 0.00% | – |
| Q1 2018 | $57,000 | -35.2% | 1,821 | -4.9% | 0.00% | – |
| Q4 2017 | $88,000 | -90.8% | 1,914 | -92.5% | 0.00% | -100.0% |
| Q3 2017 | $959,000 | -50.4% | 25,539 | -36.9% | 0.00% | -62.5% |
| Q2 2017 | $1,932,000 | +83.5% | 40,495 | +75.2% | 0.01% | +60.0% |
| Q1 2017 | $1,053,000 | +41.0% | 23,107 | -0.2% | 0.01% | +25.0% |
| Q4 2016 | $747,000 | +44.8% | 23,142 | +53.6% | 0.00% | +33.3% |
| Q3 2016 | $516,000 | +426.5% | 15,071 | +416.8% | 0.00% | +200.0% |
| Q2 2016 | $98,000 | -65.2% | 2,916 | -45.2% | 0.00% | -50.0% |
| Q1 2016 | $282,000 | -65.1% | 5,324 | -49.4% | 0.00% | -60.0% |
| Q4 2015 | $808,000 | +31.0% | 10,527 | -29.8% | 0.01% | -16.7% |
| Q3 2015 | $617,000 | +36.5% | 15,002 | +194.2% | 0.01% | +50.0% |
| Q4 2014 | $452,000 | – | 5,100 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Gagnon Advisors, LLC | 251,140 | $19,167,000 | 8.83% |
| GAGNON SECURITIES LLC | 610,933 | $46,626,000 | 7.60% |
| Tamarack Advisers, LP | 205,000 | $15,646,000 | 7.40% |
| Spyglass Capital Management LLC | 1,871,040 | $142,798,000 | 4.88% |
| Lisanti Capital Growth, LLC | 302,413 | $23,080,000 | 2.59% |
| Rock Springs Capital Management LP | 1,000,000 | $76,320,000 | 1.92% |
| MESIROW FINANCIAL INVESTMENT MANAGEMENT - Fixed Income | 208,197 | $15,890,000 | 1.76% |
| JABODON PT CO | 49,052 | $3,744,000 | 1.70% |
| Zweig-DiMenna Associates LLC | 166,675 | $12,721,000 | 1.70% |
| NEUMEIER POMA INVESTMENT COUNSEL LLC | 317,425 | $24,226,000 | 1.63% |